Etezadi Farhad, Babaie Mahsa, Larijani Amirhossein, Ketabchi Mehdi, Mojtahedzadeh Mojtaba, Jalali Ali, Alimohamadi Maysam
Department of Anesthesiology and Critical Care, Sina Hospital, Tehran University of Medical Sciences, Tehran, Iran.
Faculty of Pharmacy, Tehran University of Medical Sciences, Tehran, Iran.
Asian J Neurosurg. 2020 Oct 19;15(4):941-945. doi: 10.4103/ajns.AJNS_224_20. eCollection 2020 Oct-Dec.
Hypertonic saline (HS) has an important role in the treatment of raised intracranial pressure after traumatic brain injury. This study evaluates the efficacy and safety of HS and its impact on the postoperative course of patients undergoing craniotomy for low-grade gliomas.
Sixty patients with supratentorial low-grade glioma were enrolled. All patients were anesthetized and operated with the same team and protocol. They successively received either HS or mannitol just before surgery. The amount of brain edema was classified according to the dural tension score (I-III) just after craniotomy and before dural opening. Other intraoperative measurements (such as urine output, need, and dosage of other diuretic agents) and postoperative findings (intensive care unit [ICU] and hospital stay, corticosteroid demand, and confusion period) were also assessed. Pre- and postoperative serum S100B levels were documented in both groups.
The dural tension score was not significantly different among the two groups: severe tension in six and five patients in the mannitol and HS groups, respectively. HS group had a significantly lower amount of diuresis (609 vs. 725 ml) during surgery. Patients in the HS group had shorter ICU stay (16.3 vs. 27.9 h) and shorter duration of corticosteroid therapy after surgery (3.4 vs. 5.2 days).
HS infusion just before the onset of craniotomy is at least as effective as mannitol in controlling intraoperative brain edema in patients with supratentorial glioma. Improved early postoperative course and lower degrees of S100B rise after craniotomy seen in the HS group needs to be explained in more detailed studies.
高渗盐水(HS)在创伤性脑损伤后颅内压升高的治疗中具有重要作用。本研究评估了HS的疗效和安全性及其对接受低级别胶质瘤开颅手术患者术后病程的影响。
纳入60例幕上低级别胶质瘤患者。所有患者均由同一团队按照相同方案进行麻醉和手术。他们在手术前依次接受HS或甘露醇。根据开颅术后硬脑膜打开前的硬脑膜张力评分(I - III级)对脑水肿程度进行分类。还评估了其他术中测量指标(如尿量、其他利尿剂的需求和剂量)以及术后结果(重症监护病房[ICU]住院时间和住院时间、皮质类固醇需求以及意识模糊期)。两组均记录术前和术后血清S100B水平。
两组之间的硬脑膜张力评分无显著差异:甘露醇组和HS组分别有6例和5例患者出现严重张力。HS组手术期间的尿量明显较少(609 vs. 725 ml)。HS组患者的ICU住院时间较短(16.3 vs. 27.9小时),术后皮质类固醇治疗持续时间较短(3.4 vs. 5.2天)。
开颅手术开始前输注HS在控制幕上胶质瘤患者术中脑水肿方面至少与甘露醇一样有效。HS组术后早期病程改善以及开颅术后S100B升高程度较低的情况需要在更详细的研究中加以解释。